How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

OBJECTIVE: Regulatory agencies require the assessment of cardiovascular (CV) safety for new type 2 diabetes (T2D) therapies through CV outcome trials (CVOTs). However, patients included in CVOTs assessing sodium-glucose cotransporter-2 inhibitors (SGLT2i) might not be representative of those seen in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Diabetes Res
Main Authors: Canivell, Silvia, Mata-Cases, Manel, Vlacho, Bogdan, Gratacòs, Mònica, Real, Jordi, Mauricio, Dídac, Franch-Nadal, Josep
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877986/
https://ncbi.nlm.nih.gov/pubmed/31815146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/2018374
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados